Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures
It is established that combined KRAS and BCL-2 inhibition elicits pyroptosis and TLS formation, leading to B-cell-dependent in situ and memory antitumor immunity, providing a mechanistic rationale for targeting mitochondrial-immune crosstalk in KRAS G12D-mutant lung cancer.